The March 2017 issue of Pharmafocus is now live!

pharmafile | February 22, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo 

The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing in precision medicine, its a packed issue.

Trump is backing up the hard-line promises he made during his campaign trail; in a recent meeting with pharma leaders, he called for massive regulation cuts in the sector to accelerate drug access. We look at the potential threat this poses to the FDA in our lead story. We also examine the rising threat of antibiotic resistance and the latest research to combat it, and pick apart the Johnson & Johnson/Actelion deal which made the headlines this month.

Drug pricing is a constant inssue in the industry, and this month in our major feature we delve into how the issue is developing in the EU within the context of the current financial crises and the curveball of Brexit. We also speak to MSD and Roche in our second feature to discuss how their immuno-oncology therapies are threatening market leader Opdivo, and what the new wave of medicines means for the treatment of cancer.

Precision medicine is gathering support rapidly for its potential to change the face of patient treatment. Amongst the technologies pushing this movement is gene-editing tool CRISPR, and we examine what it could mean for personalised therapies in our third feature.

We speak to Warwick Smith, Director of the British Generic Manufacturer’s Association, for his thoughts on the recent news in the UK of skyrocketing generic drug prices, while Dr Dilruwan Chaminda Herath discusses whether the lack of good clinical trials practice in pharma recruitment poses a risk to the industry in the advent of real world data.

Related Content

FDA grants marketing authorisation to DNA test for predisposition to certain cancers

The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …

Biogen’s biosimilar Tofidence approved by FDA

Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) …


Karuna Therapeutics submits NDA to FDA for schizophrenia treatment

Karuna Therapeutics has announced that it has submitted a New Drug Application (NDA) to the …

Latest content